Fundraising Fox
/Companies
Sign in

Cardurion

Burlington, US · Founded 2017 · 74 employees on LinkedIn · 12 known investors

Find your way into Cardurion

Sign up to see every warm intro you have to Cardurion

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Cardurion team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with GoogleAlready have an account? Log in

Cardurion is a cardiovascular disease-focused company developing therapeutics, with a pipeline advanced through clinical development, trial design, regulatory affairs, and commercialization. It draws on a board of cardiovascular disease experts and industry veterans to guide its drug development.

BiotechDigital HealthHealthtechMedical Devices

Founders & leadership

Cardurion was founded in 2017 by Michael E. Mendelsohn.

MEMichael E. Mendelsohn
Michael E. MendelsohnFounder and Chief Strategy OfficerMichael E. Mendelsohn is a physician-scientist with over 25 years of academic cardiovascular research experience at Tufts Medical Center and Brigham and Women's Hospital, and served as Senior Vice President and Global Franchise Head of Cardiovascular Diseases at Merck & Co. from 2010–2013 before founding Cardurion Pharmaceuticals.

Investors · 12

Ascenta Capitallisted by Ascenta CapitalWilmington · $15M – $30M

How we know: finance.yahoo.com · funding news · Not right? Tell us

Delos Capitallisted by Delos CapitalCambridge

How we know: press coverage · Not right? Tell us

Digitalis Ventureslisted by Digitalis VenturesNew York · $100K – $10M

How we know: Digitalis Ventures's portfolio page · press coverage · the VCSheet dataset · Not right? Tell us

New Enterprise Associates (NEA)listed by New Enterprise Associates (NEA)Menlo Park · $200K – $40M

How we know: finance.yahoo.com · Not right? Tell us

Bain Capital Life SciencesreportedBoston

How we know: finance.yahoo.com · Not right? Tell us

Bain Capital Tech OpportunitiesreportedBoston

How we know: press coverage · Not right? Tell us

Fidelity InvestmentsreportedBoston

How we know: press coverage · Not right? Tell us

GV (Google Ventures)reportedMountain View · $250K – $50M

How we know: finance.yahoo.com · Not right? Tell us

InvusreportedNew York

How we know: press coverage · Not right? Tell us

Millennium ManagementreportedNew York

How we know: press coverage · Not right? Tell us

Also in the syndicate · 1

Bain

Funding

SEC filings, press & company announcements

$260M disclosed across 1 of 2 rounds · 2024

Source: company announcements and press reports — follow each round's link for the claim.

In the news

Cardurion Raises $260M to Advance Cardiovascular Assets - BioSpacebiospace.com · Jul 2024Cardurion raises another $260M to fuel heart drug pipelinefinance.yahoo.com · Jul 2024

Frequently asked questions

What does Cardurion do?
Cardurion is a cardiovascular disease-focused company developing therapeutics, with a pipeline advanced through clinical development, trial design, regulatory affairs, and commercialization. It draws on a board of cardiovascular disease experts and industry veterans to guide its drug development.
Who founded Cardurion?
Cardurion was founded by Michael E. Mendelsohn in 2017.
Who are Cardurion's investors?
Cardurion's investors include Bain Capital, Ascenta Capital, Delos Capital, Digitalis Ventures, New Enterprise Associates (NEA), Bain Capital Life Sciences, Bain Capital Tech Opportunities, Fidelity Investments and 3 more.
How much funding has Cardurion raised?
Cardurion has disclosed $260M raised across 1 of its 2 known rounds.
Where is Cardurion headquartered?
Cardurion is headquartered in Burlington, US.